US11786501B2ActiveUtilityA1

Nitroxyl donors with improved therapeutic index

93
Assignee: CARDIOXYL PHARMACEUTICALS INCPriority: Jan 18, 2013Filed: Mar 14, 2022Granted: Oct 17, 2023
Est. expiryJan 18, 2033(~6.5 yrs left)· nominal 20-yr term from priority
Inventors:Vincent Jacob KalishFrederick Arthur BrookfieldStephen Martin CourtneyLisa Marie FrostJohn P. Toscano
A61P 9/00C07D 307/64C07C 317/14A61K 31/341A61K 9/0019A61K 9/08A61K 31/18A61K 31/222A61K 31/24A61K 31/255A61K 31/343A61K 31/381A61K 31/404A61K 31/42A61K 31/433A61K 31/4436A61K 31/538A61K 31/5377A61K 47/12A61K 47/40A61P 9/04
93
PatentIndex Score
1
Cited by
256
References
11
Claims

Abstract

The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method of treating ischemia/reperfusion injury, comprising administering an effective amount of a compound of formula (1), or a pharmaceutical composition comprising the compound of formula (1), to a patient in need thereof, wherein the compound of formula (1) is represented by formula: 
       
         
           
           
               
               
           
         
       
     
     
       2. The method of  claim 1 , wherein the compound or the pharmaceutical composition is administered intravenously. 
     
     
       3. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 1 ug/kg/min. 
     
     
       4. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 2.5 ug/kg/min. 
     
     
       5. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 5 ug/kg/min. 
     
     
       6. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 7.5 ug/kg/min. 
     
     
       7. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 12 ug/kg/min. 
     
     
       8. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 15 ug/kg/min. 
     
     
       9. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of no more than about 30 ug/kg/min. 
     
     
       10. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of from about 1 ug/kg/min to about 100 ug/kg/min. 
     
     
       11. The method of  claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of from about 2.5 ug/kg/min to about 100 ug/kg/min.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.